Prot# CTCH346A2211: A Rndmzd, Dbl-Blnd, Placebo-Cntrlld, Stratified, Parallel-Group, Multicenter, Dose-Ranging Study Evaluating 4 Oral Doses of TCH346(1.0, 2.5, 7.5 & 15 mg)Administered 1x Daily in Patients w/Amyotrophic Lateral Sclerosis

Project: Research project

Project Details

StatusFinished
Effective start/end date6/1/03 → 1/1/11

Funding

  • Novartis Pharmaceuticals Corporation (CTCH346A2211)